For example, Suzuki and colleagues engineered OAV to express an anti-PD-L1-blocking mini-antibody (CAd-VECPDL1) to enhance CAR T-cell killing action.353 This anti-PD-L1 mini antibody was detected at the tumor site after CAd-VECPDL1 administration. This evidence concerns the gene CD274 and neoplasm.